(Q40994161)

25 September 2017

CEA TCB: A novel head-to-tail 2:1 T cell bispecific antibody for treatment of CEA-positive solid tumors (English)

1 reference

25 September 2017

Marina Bacac

1

1 reference

PMC publication ID

5007959

25 September 2017

Christian Klein

series ordinal

2

1 reference

PMC publication ID

5007959

25 September 2017

Pablo Umana

series ordinal

3

1 reference

25 September 2017

24 June 2016

1 reference

25 September 2017

1 reference

25 September 2017

5

1 reference

25 September 2017

8

1 reference

25 September 2017

e1203498

1 reference

Creative Commons Attribution-NonCommercial 3.0 Unported

25 September 2017

start time

24 June 2016

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

cites work

In Vivo Fluorescence Imaging of the Activity of CEA TCB, a Novel T-Cell Bispecific Antibody, Reveals Highly Specific Tumor Targeting and Fast Induction of T-Cell-Mediated Tumor Killing.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5007959

A novel, native-format bispecific antibody triggering T-cell killing of B-cells is robustly active in mouse tumor models and cynomolgus monkeys

25 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5007959

Therapeutic bispecific T-cell engager antibody targeting the intracellular oncoprotein WT1.

25 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5007959

FDA Approval: Blinatumomab

25 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5007959

Anti-CD20/CD3 T cell-dependent bispecific antibody for the treatment of B cell malignancies

25 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5007959

Targeting T cells to tumor cells using bispecific antibodies

25 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5007959

The CEA/CD3-bispecific antibody MEDI-565 (MT111) binds a nonlinear epitope in the full-length but not a short splice variant of CEA

25 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5007959

Tumor regression in cancer patients by very low doses of a T cell-engaging antibody

25 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5007959

Application of a MABEL Approach for a T-Cell-Bispecific Monoclonal Antibody: CEA TCB.

25 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5007959

A Novel Carcinoembryonic Antigen T-Cell Bispecific Antibody (CEA TCB) for the Treatment of Solid Tumors.

19 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5007959

10.1080/2162402X.2016.1203498

19 August 2018

Identifiers

DOI

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/rgqqwflkzvh3bgyg554pirg6ge

30 July 2022

release_rgqqwflkzvh3bgyg554pirg6ge

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/rgqqwflkzvh3bgyg554pirg6ge

30 July 2022

https://api.fatcat.wiki/v0/release/rgqqwflkzvh3bgyg554pirg6ge

1 reference

30 July 2022

https://api.fatcat.wiki/v0/release/rgqqwflkzvh3bgyg554pirg6ge

PubMed publication ID

1 reference

30 July 2022